Development of Prodrugs for Enzyme-Mediated, Tumor-Selective Therapy

Title: Development of Prodrugs for Enzyme-Mediated, Tumor-Selective Therapy

Volume: 5 Issue: 2

Author(s): K. Jin Yoon, Philip M. Potter and Mary K. Danks

Affiliation:

Keywords: enzyme prodrug therapy, hsv-tk gcv, Herves Simplex Virus-Thymidine Kinase Ganciclovir, cd 5-fc, cytosine deaminase 5-fluorocytosine, pnpase 2-f-araa, purine nucleoside phosphorylase 2-fluoroarabinosyl adenine

Abstract: Anticancer enzyme / prodrug approaches to therapy are designed to activate prodrugs specifically at tumor loci, to achieve antitumor responses with minimal toxicity. The equivocal success of these approaches thus far has led to searches for more efficient combinations. This mini-review evaluates and compares characteristics of seven selected enzyme / prodrug combinations, and discusses goals for future development of effective combinations.

Cite this article as:

Yoon Jin K., Potter M. Philip and Danks K. Mary, Development of Prodrugs for Enzyme-Mediated, Tumor-Selective Therapy, Current Medicinal Chemistry - Anti-Cancer Agents 2005; 5 (2) . https://dx.doi.org/10.2174/1568011053174837